One of the fastest-growing segments of pharmaceuticals, as highlighted at the 2024 J.P. Morgan Healthcare Conference, is the antibody-drug conjugate (ADC) segment. ADCs consist of four main elements: ...
When a patient is diagnosed with a bacterial infection, medical staff need to identify the species attacking the body before it can be treated. The problem is, this process can take a few days and may ...
Lonza entered into two new collaborations with McSAF and Cristal Therapeutics to expand its bioconjugates offering. The collaborations are geared to enable the integration of two novel conjugation ...
Lonza and Singzyme will use Singzyme’s enzymatic conjugation platform to develop novel bioconjugates. Lonza and Singzyme, a biotechnology company specializing in developing enzymes for protein ...
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC The extended relationship builds ...
This panel will present a focused playbook for biopharma patent practitioners allowing them to protect the full scope of innovation reflected in the biologic development process. The discussion will ...
Lonza today announced a long-term, strategic collaboration for bioconjugation with a global biopharma company. Under the terms of the agreement, Lonza will construct two new customer-dedicated ...
WuXi Biologics and WuXi STA have established a joint venture company named WuXi XDC to provide contract development and manufacturing of bioconjugates, including antibody-drug conjugates. WuXi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results